257 related articles for article (PubMed ID: 31166020)
1. Forced oscillation technique as method to document and monitor the efficacy of mepolizumab in treating severe eosinophilic asthma.
Antonicelli L; Tontini C; Marchionni A; Lucchetti B; Garritani MS; Bilò MB
Allergy; 2020 Feb; 75(2):433-436. PubMed ID: 31166020
[No Abstract] [Full Text] [Related]
2. Mepolizumab: First Global Approval.
Keating GM
Drugs; 2015 Dec; 75(18):2163-9. PubMed ID: 26603873
[TBL] [Abstract][Full Text] [Related]
3. Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.
Hilvering B; Xue L; Pavord ID
Ther Adv Respir Dis; 2015 Aug; 9(4):135-45. PubMed ID: 25900924
[TBL] [Abstract][Full Text] [Related]
4. Severe Eosinophilic Allergic Asthma Responsive to Mepolizumab After Failure of 2 Consecutive Biologics.
Sánchez-Jareño M; Barranco P; Romero D; Domínguez-Ortega J; Quirce S
J Investig Allergol Clin Immunol; 2019 Feb; 29(1):79-81. PubMed ID: 30785114
[No Abstract] [Full Text] [Related]
5. Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab.
Pelaia C; Vatrella A; Busceti MT; Gallelli L; Terracciano R; Savino R; Pelaia G
Drug Des Devel Ther; 2017; 11():3137-3144. PubMed ID: 29133975
[TBL] [Abstract][Full Text] [Related]
6. Severe asthma with eosinophilic gastroenteritis effectively managed by mepolizumab and omalizumab.
Han D; Lee JK
Ann Allergy Asthma Immunol; 2018 Dec; 121(6):742-743. PubMed ID: 30056148
[No Abstract] [Full Text] [Related]
7. Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis.
Numata T; Nakayama K; Utsumi H; Kobayashi K; Yanagisawa H; Hashimoto M; Minagawa S; Ishikawa T; Hara H; Araya J; Kuwano K
BMC Pulm Med; 2019 Oct; 19(1):176. PubMed ID: 31606052
[TBL] [Abstract][Full Text] [Related]
8. [Severe refractory eosinophilic asthma].
Jäger-Becker D
MMW Fortschr Med; 2016 Feb; 158(3):67. PubMed ID: 27119709
[No Abstract] [Full Text] [Related]
9. Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype.
Gupta A; Ikeda M; Geng B; Azmi J; Price RG; Bradford ES; Yancey SW; Steinfeld J
J Allergy Clin Immunol; 2019 Nov; 144(5):1336-1342.e7. PubMed ID: 31425781
[TBL] [Abstract][Full Text] [Related]
10. Reslizumab (Cinqair) for severe eosinophilic asthma.
Med Lett Drugs Ther; 2016 Jun; 58(1497):81-2. PubMed ID: 27305070
[No Abstract] [Full Text] [Related]
11. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma.
Khatri S; Moore W; Gibson PG; Leigh R; Bourdin A; Maspero J; Barros M; Buhl R; Howarth P; Albers FC; Bradford ES; Gilson M; Price RG; Yancey SW; Ortega H
J Allergy Clin Immunol; 2019 May; 143(5):1742-1751.e7. PubMed ID: 30359681
[TBL] [Abstract][Full Text] [Related]
12. Favorable clinical efficacy of mepolizumab on the upper and lower airways in severe eosinophilic asthma: a 48-week pilot study.
Kurosawa M; Ogawa E; Sutoh E
Eur Ann Allergy Clin Immunol; 2019 Sep; 51(5):213-221. PubMed ID: 30983308
[No Abstract] [Full Text] [Related]
13. Mepolizumab: A Review in Eosinophilic Asthma.
Deeks ED
BioDrugs; 2016 Aug; 30(4):361-70. PubMed ID: 27311938
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Treatment With Anti-Interleukin 5 Antibodies in a Patient with Chronic Eosinophilic Pneumonia.
Shimizu Y; Kurosawa M; Sutoh Y; Sutoh E
J Investig Allergol Clin Immunol; 2020 Apr; 30(2):154-155. PubMed ID: 31778113
[No Abstract] [Full Text] [Related]
15. Efficacy of anti-interleukin-5 therapy with mepolizumab in patients with asthma: a meta-analysis of randomized placebo-controlled trials.
Liu Y; Zhang S; Li DW; Jiang SJ
PLoS One; 2013; 8(3):e59872. PubMed ID: 23544105
[TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy of anti-IL-5 monoclonal antibody mepolizumab in the treatment of eosinophilic otitis media.
Iino Y; Takahashi E; Ida S; Kikuchi S
Auris Nasus Larynx; 2019 Apr; 46(2):196-203. PubMed ID: 30122651
[TBL] [Abstract][Full Text] [Related]
17. Real-life evaluation of the clinical, functional, and hematological effects of mepolizumab in patients with severe eosinophilic asthma: Results of a single-centre observational study.
Pelaia C; Busceti MT; Solinas S; Terracciano R; Pelaia G
Pulm Pharmacol Ther; 2018 Dec; 53():1-5. PubMed ID: 30217438
[TBL] [Abstract][Full Text] [Related]
18. Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience.
Emma R; Morjaria JB; Fuochi V; Polosa R; Caruso M
Ther Adv Respir Dis; 2018; 12():1753466618808490. PubMed ID: 30354852
[TBL] [Abstract][Full Text] [Related]
19. Blood eosinophil phenotype during treatment with mepolizumab in patients with severe eosinophilic asthma.
Sakai C; Matsuyama M; Nakajima M; Matsumura S; Nonaka M; Arai N; Kuramoto K; Yoshida K; Morishima Y; Muratani M; Hizawa N
Allergol Int; 2024 Jul; 73(3):473-476. PubMed ID: 38582716
[No Abstract] [Full Text] [Related]
20. Controversies in Allergy: Should Severe Asthma with Eosinophilic Phenotype Always Be Treated with Anti-IL-5 Therapies.
Pavord ID; Hanania NA
J Allergy Clin Immunol Pract; 2019; 7(5):1430-1436. PubMed ID: 30962155
[No Abstract] [Full Text] [Related]
[Next] [New Search]